...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Reversal of the inhibitory effect of Fondaparinux on Thrombin generation by rFVIIa, aCCP and PCC.
【24h】

Reversal of the inhibitory effect of Fondaparinux on Thrombin generation by rFVIIa, aCCP and PCC.

机译:通过rFVIIa,aCCP和PCC逆转了Fondaparinux对凝血酶的抑制作用。

获取原文
获取原文并翻译 | 示例

摘要

Adverse events associated with the administration of fondaparinux are mainly bleeding complications. Fondaparinux lacks specific antidotes and there is no routine laboratory assay for monitoring the efficacy of fondaparinux. Thrombin generation test measures the kinetic of thrombin formation over time which is a more complete characterisation of the individual coagulation capacity than classical clot based assays. In the present study the reversal effect of three procoagulant molecules was tested on the anticoagulant effect of fondaparinux. A complete correction of thrombin generating capacity was found with low doses of Feiba while rFVIIa was responsible for a partial correction of the coagulation capacity.
机译:与磺达肝癸钠给药相关的不良事件主要是出血并发症。 Fondaparinux缺乏特异性解毒剂,并且没有常规的实验室检测方法来监测fondaparinux的疗效。凝血酶生成测试可测量凝血酶随时间变化的动力学,这比传统的基于凝块的测定法更能完整地表征单个凝血能力。在本研究中,测试了三种促凝剂分子对磺达肝素的抗凝作用的逆转作用。低剂量的Feiba可以完全纠正凝血酶的产生能力,而rFVIIa可以部分纠正凝血能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号